Catherine Skari

TIF PATIENTS & HEALTHCARE PROFESSIONALS CAPACITY BUILDING WORKSHOP | 16-19 May 2024

Read More »

Alpha-Thalassemia: A Practical Overview

α-Thalassemia is an inherited blood disorder characterized by decreased synthesis of α-globin chains that results in an imbalance of α and β globin and…

Read More »

EXCLUSIVE WEBINAR | Guidelines for the Management of a-Thalassaemia |14 March 2024

📌 Webinar Title: Guidelines for the Management of α-Thalassaemia 📌 Date & Time: Thursday, March 14, 2024, 13:00 Bangkok /…

Read More »

SPOTLIGHT | RAIN Endorses the First International Guidelines for Pyruvate Kinase Deficiency

Pyruvate kinase deficiency (PKD) is the most common cause of chronic congenital non-spherocytic haemolytic anaemia, impacting between one in 100,000…

Read More »

The Italian Breakthrough in CRISPR trials for Rare Diseases: A focus on β-Thalassemia and Sickle Cell Disease Treatment

The development of gene therapy and the current advantageous method of clustered regularly interspaced short palindromic repeats (CRISPRs) has allowed…

Read More »

REGULATORY NEWS | AstraZeneca’s Voydeya Recommended for PNH Treatment in EU

Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of care Ultomiris (ravulizumab) or Soliris (eculizumab) to address the…

Read More »

Pain Impact and Management in Individuals With Transfusion-Dependent Thalassaemia

Over the last several decades, there has been significant progress in addressing the main symptoms and related health issues of…

Read More »

ELEVATING AWARENESS | 29 February Is Rare Disease Day

Rare Disease Day is the globally-coordinated movement on rare diseases, working towards equity in social opportunity, healthcare, and access to…

Read More »

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | Ruxoprubart Scores FDA Orphan Drug Designation for PNH Treatment

FDA’s recognition of Ruxoprubart as an orphan drug for PNH underscores its potential to fulfill a crucial need for individuals…

Read More »

BREAKING NEWS | TIF’s Collaboration with WHO Extended to 2027

Our enduring collaboration was newly endorsed by WHO’s Executive Board at its 154th session in January 2024, demonstrating our significant…

Read More »